Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM-Reference-Cited by-同舟云学术

Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM

Published:2019-08-01 Issue:22 Volume:37 Page:1982-1983
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Goetz Matthew P.¹,Suman Vera J.¹,Nakamura Yusuke¹,Kiyotani Kazuma¹,Jordan V. Craig¹,Ingle James N.¹

Affiliation:

1. Matthew P. Goetz, MD and Vera J. Suman, PhD, Mayo Clinic, Rochester, MN; Yusuke Nakamura, MD, PhD and Kazuma Kiyotani, PhD, Cancer Precision Medicine Center, Tokyo, Japan; V. Craig Jordan, PhD, DSc, The University of Texas MD Anderson Cancer Center, Houston, TX; and James N. Ingle, MD, Mayo Clinic, Rochester, MN

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.19.00504

Reference10 articles.

1. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study

2. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies

3. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

4. CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations

5. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes;Cancer Research and Treatment;2024-01-15

2. Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer;Breast Cancer Research and Treatment;2023-04-17

3. Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects;Pharmacogenetics and Genomics;2022-11-07

4. Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial;Clinical Drug Investigation;2022-01-12

5. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer;Clinical Pharmacokinetics;2021-11-17